CoChat

Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes

Open access
Sharma, Geetanjali, Hu, Chelin, Staquicini, Daniela I., Brigman, Jonathan L., Liu, Meilian, Mauvais-Jarvis, Franck, Pasqualini, Renata, Arap, Wadih, Arterburn, Jeffrey B., Hathaway, Helen J., Prossnitz, Eric R. · 2020 · Science Translational Medicine
Cited by 105

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Human obesity has become a global health epidemic, with few safe and effective pharmacological therapies currently available. The systemic loss of ovarian estradiol (E2) in women after menopause greatly increases the risk of obesity and metabolic dysfunction, revealing the critical role of E2 in this setting. The salutary effects of E2 are traditionally attributed to the classical estrogen receptors ERα and ERβ, with the contribution of the G protein–coupled estrogen receptor (GPER) still largely unknown. Here, we used ovariectomy- and diet-induced obesity (DIO) mouse models to evaluate the preclinical activity of GPER-selective small-molecule agonist G-1 (also called Tespria) against obesity and metabolic dysfunction. G-1 treatment of ovariectomized female mice (a model of postmenopausal obesity) reduced body weight and improved glucose homeostasis without changes in food intake, fuel source usage, or locomotor activity. G-1–treated female mice also exhibited increased energy expenditure, lower body fat content, and reduced fasting cholesterol, glucose, insulin, and inflammatory markers but did not display feminizing effects on the uterus (imbibition) or beneficial effects on bone health. G-1 treatment of DIO male mice did not elicit weight loss but prevented further weight gain and improved glucose tolerance, indicating that G-1 improved glucose homeostasis independently of its antiobesity effects. However, in ovariectomized DIO female mice, G-1 continued to elicit weight loss, reflecting possible sex differences in the mechanisms of G-1 action. In conclusion, this work demonstrates that GPER-selective agonism is a viable therapeutic approach against obesity, diabetes, and associated metabolic abnormalities in multiple preclinical male and female models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aau5956

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 105

Metadata

Authors
Sharma, G., Hu, C., Staquicini, D. I., Brigman, J. L., Liu, M., Mauvais-Jarvis, F., Pasqualini, R., Arap, W., Arterburn, J. B., Hathaway, H. J., & Prossnitz, E. R.
Venue
Science Translational Medicine
Published
2020-01-29
Volume
12
Issue
528
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3003989813
Cited by
105
References
20
FWCI
8.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes. https://app.cochat.ai/papers/10.1126/scitranslmed.aau5956
The paper
Sharma, G., Hu, C., Staquicini, D. I., Brigman, J. L., Liu, M., Mauvais-Jarvis, F., Pasqualini, R., Arap, W., Arterburn, J. B., Hathaway, H. J., & Prossnitz, E. R. (2020). Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aau5956

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.